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Introduction
============

Signal transduction pathways control multiple aspects of cellular behavior, including regulating the connectivity between cells and their adhesion to external surfaces. Among the signaling proteins that regulate cell adhesion are members of the mucin family of proteins. Signaling mucins are cell-surface proteins composed of a heavily glycosylated extracellular domain that contains a Ser/Thr/Pro-rich mucin homology domain (MHD; [@bib43]), which is connected to a cytoplasmic domain that regulates RAS/RHO GTPases and their effector MAPK pathways ([@bib6]). Proteolytic processing separates the domains and results in the shedding of the extracellular glycodomain from the cell ([@bib45]). Signaling mucins also contribute to the regulation of other pathways including the Wnt, nuclear factor-κβ, and estrogen receptor pathways ([@bib18]; [@bib48]).

In *Saccharomyces cerevisiae*, the signaling mucin Msb2p regulates MAPK activity by interaction with the RHO GTPase Cdc42p ([@bib11]), a global regulator of cell signaling and polarity ([@bib19]). Cdc42p and its effector kinase Ste20p regulate multiple MAPK pathways including the filamentous growth ([@bib31]; [@bib23]), pheromone response ([@bib44]), and high osmolarity glycerol response (HOG) pathways ([@bib47]). Differential MAPK activation is regulated in part by pathway-specific MAPKs ([@bib26]) and recruitment of core signaling modules to pathway-dedicated receptor complexes by scaffolding proteins ([@bib5]; [@bib17]). Msb2p is required for activation of the filamentous growth pathway ([@bib11]) and may function in a minor way in the HOG pathway ([@bib30]). Indeed, Msb2p associates with the tetraspan protein Sho1p ([@bib11]), which operates in both the filamentous growth and HOG pathways ([@bib27]; [@bib11]; [@bib49]). Although it is unclear how Msb2p becomes activated, loss of the MHD induces the signaling function of the protein, which suggests an inhibitory role for this domain in MAPK signaling ([@bib11]).

In the present study, we show that Msb2p, like its mammalian counterparts, is processed into secreted and cell-associated forms. This discovery, coupled with the fact the secreted domain of Msb2p is inhibitory, suggests a mechanism where processing and release of the extracellular domain activates the protein. We confirmed this hypothesis and identified an aspartyl protease, Yps1p, that is required for Msb2p processing. Intriguingly, the gene encoding Yps1p is induced in response to nutrient limitation, which provides a straightforward mechanism for regulated processing of Msb2p. We speculate that cleavage-dependent activation may be a general feature of mucin receptors.

Results and discussion
======================

Msb2p is processed into distinct polypeptides
---------------------------------------------

The extracellular portion of the Msb2p protein was detected in supernatants by Western blotting, which indicates that it is secreted from the cell. To determine if secretion results from processing in the extracellular domain, a version of the protein was examined in which the extracellular (HA, at 500 residues) and cytoplasmic (GFP, at 1,306 residues) domains were differentially tagged. Conditioned media derived from cells expressing HA-Msb2p-GFP showed that the extracellular but not cytoplasmic domain was secreted ([Fig. 1 A](#fig1){ref-type="fig"}). This result confirms topological and subcellular fractionation data that indicate that Msb2p is a membrane-spanning protein ([@bib11]). Although the extracellular domain of Msb2p migrated as a single heavily glycosylated product at \>250 kD, the cytoplasmic domain migrated as multiple intermediate forms ([Fig. 1 A](#fig1){ref-type="fig"}), which indicates that it is unstable. Consistent with this result, the extracellular portion of Msb2p tagged with GFP was found evenly distributed throughout the cell ([Fig. 1 B](#fig1){ref-type="fig"}), whereas the cytoplasmic domain tagged with GFP was predominately localized to vacuoles ([Fig. 1 B](#fig1){ref-type="fig"}). These results indicate that Msb2p is processed into multiple polypeptides with different stabilities and localization patterns.

![**Msb2p is processed in the cleavage domain and the extracellular portion of the protein is secreted.** (A) Western blot of supernatant (S) and pellet (P) fractions derived from cells containing HA-Msb2p-GFP. (left) Anti-HA antibodies. (right) Anti-GFP antibodies. The band at 25 kD migrates at the predicted size of GFP. (B) Localization of Msb2p containing GFP inserted into the extracellular and cytoplasmic domains. (top) Differential interference contrast. (bottom) FITC. Bar, 5 μm. (C) Deletion analysis of *MSB2*. Top lines, potential glycosylation sites; bottom lines, basic residues. (D) Western blot of S and P fractions derived from cells expressing HA-Msb2p deletions. Molecular mass standards (kD) are indicated on the left of the gel blots.](jcb1811073f01){#fig1}

Deletion analysis of the *MSB2* ORF was performed to identify the region of the protein required for secretion ([Fig. 1 C](#fig1){ref-type="fig"}). Versions of Msb2p containing deletions in the extracellular domain (*100-818Δ, 100--850Δ*, and *100-900Δ*) were secreted ([Fig. 1, C and D](#fig1){ref-type="fig"}), as was the version *100-950Δ*, although to a lesser extent ([Fig. 1, C and D](#fig1){ref-type="fig"}). Additional deletion analysis was performed using HA-Msb2p as the template because epitope fusions in the cytoplasmic domain were unstable and difficult to detect. An extracellular region of the protein adjacent to the transmembrane (TM) domain was identified that was required for secretion (cleavage domain \[CD\] 1,045--1,145 residues; [Fig. 1, C and D](#fig1){ref-type="fig"}). The CD overlaps with the predicted cleavage site by Western blotting (the 55-kD product in [Fig. 1 A](#fig1){ref-type="fig"}) and resides between the glycosylation-rich extracellular domain and basic C terminus ([Fig. 1 C](#fig1){ref-type="fig"}). A version of Msb2p lacking the TM and cytoplasmic domains was secreted at higher levels (*TM-CYT*Δ; [Fig. 1, C and D](#fig1){ref-type="fig"}), which is consistent with the idea that the TM domain anchors Msb2p to the plasma membrane.

The aspartyl protease Yps1p processes Msb2p
-------------------------------------------

To identify the protease required for Msb2p processing, protein processing mutants from the ordered deletion collection ([@bib12]) were examined for defects in secretion of HA-Msb2p. One mutant stood out as partially defective (*yps1*Δ; Table S3, available at <http://www.jcb.org/cgi/content/full/jcb.200704079/DC1>). Yps1p is a member of a family of glycosylphosphatidylinositol (GPI)-anchored aspartyl proteases called yapsins (Yps1p, Mkc7/Yps2p, Yps3p, Yps6p, and Yps7p; [@bib21]). HA-Msb2p was poorly secreted in the *yps1*Δ mutant, more so than other *yps* single mutants ([Fig. 2 A](#fig2){ref-type="fig"}). Combinations of *yps* mutants showed combinatorial defects with *yps1*Δ including *yps1*Δ *mkc7*Δ, *yps1*Δ *yps3*Δ, and the quintuple mutant *5ypsΔ* ([Fig. 2 A](#fig2){ref-type="fig"}), which indicates a minor role for other Yps proteins in Msb2p processing. Introduction of *YPS1* on a centromere-based plasmid rescued the majority of the secretion defect of HA-Msb2p in the *5ypsΔ* strain (Fig. S1 A), confirming that Yps1p is the primary Yps protease required for Msb2p processing.

![**The role of yapsin proteases in Msb2p processing.** (A) Western blot analysis of the secretion defect of HA-Msb2p in *yps* mutants. Molecular mass standards (kD) are indicated on the left of the gel blots. P, pellet; S, supernatant. (B) Msb2p-GFP localization in WT, *yps1Δ*, and *5ypsΔ* strains. Bar, 10 μm.](jcb1811073f02){#fig2}

Yps1p has been shown to process heterologously expressed glycoprotein substrates by cleavage in the extracellular domain at monobasic residues ([@bib4]). By these criteria, Msb2p is a likely substrate of Yps1p and the first physiological target to be identified. Several lines of evidence support this possibility. First, *yps* mutants are not generally defective in protein secretion, and several proteins have been examined that are secreted in *yps* mutants to wild type (WT) or higher levels (unpublished data). The Msb2p protein was delivered to the cell surface in *yps* mutants based on the fact that HA-Msb2p lacking its TM domain was secreted in the 5*ypsΔ* mutant ([Fig. 2 A](#fig2){ref-type="fig"}). Intriguingly, Msb2p-GFP was absent from vacuoles in *yps* mutants ([Fig. 2 B](#fig2){ref-type="fig"}). Several other cell-surface proteins showed a similar localization pattern (unpublished data), which suggests a general requirement for Yps proteins in delivery of a subset of cell-surface proteins to vacuoles. Second, although *yps* mutants have defects in cell integrity and cell wall biosynthesis ([@bib21]), secretion of HA-Msb2p was not restored by conditional rescue of the cell integrity defect of the *5ypsΔ* mutant grown in 1 M sorbitol ([Fig. 2 A](#fig2){ref-type="fig"}). Likewise, cell-wall mutant combinations defective for β-1,3 and β-1,6-glucan synthesis that mimic *yps* phenotypes showed elevated secretion of HA-Msb2p (Fig. S1 B). Third, the *yps1Δ* mutant was defective in processing Msb2p-TAP, resulting in accumulation of the full-length protein and loss of a processing intermediate (Fig. S1 C).

Cleavage of Msb2p is required for MAPK activation and is stimulated by nutrient limitation--dependent induction of YPS1 expression
----------------------------------------------------------------------------------------------------------------------------------

Msb2p lacking the MHD hyperactivates the filamentous growth pathway ([@bib11]). Versions of Msb2p lacking larger portions of the extracellular domain were also hyperactive, more so than Msb2p^ΔMHD^ ([Fig. 3 A](#fig3){ref-type="fig"}), which confirms that the extracellular domain (from 100 to 950 residues) functions in an inhibitory capacity. Cleavage of the inhibitory domain may provide an explanation for how the protein becomes activated. In support of this possibility, the noncleavable version of Msb2p, Msb2p^ΔCD^, was defective for MAPK activity ([Fig. 3 A](#fig3){ref-type="fig"}) and filamentous growth (not depicted). Versions of Msb2p lacking the TM and CYT domains were similarly defective for signaling ([Fig. 3 A](#fig3){ref-type="fig"}).

![**Cleavage of Msb2p induces MAPK signaling and is regulated at the level of *YPS1* expression.** (A) *FUS1-lacZ* expression in strains containing Msb2p deletions. (B) Western blot of HA-Msb2p in WT and *yps1Δ* strains grown in mid-log phase yeast extract peptone dextrose (YEPD) or YEP-GAL (YEPG) medium for 1 and 3 d. Dpm1p was used as a loading control (Ctl). Molecular mass standards (kD) are indicated on the left of the gel blots. (C) *YPS1-lacZ* expression in cells incubated in mid-log phase in SCD (Glu) or SC-Gal (Gal) medium for 1and 3 d. (D) *FUS1-lacZ* expression in indicated strains overexpressing *YPS1* and *MKC7*. Error bars represent the standard deviation of the values derived from at least two separate experiments. (E) Cell morphology in strains containing high copy (2 μm) *YPS1*. Bar, 5 μm.](jcb1811073f03){#fig3}

To determine if Msb2p processing is regulated, secretion of Msb2p was examined in cells incubated under different conditions, particularly nutrient limitation, a known inducer of filamentous growth ([@bib8]). Secretion of HA-Msb2p was induced \>10-fold by nutrient limitation, and the enhanced secretion was Yps1p dependent ([Fig. 3 B](#fig3){ref-type="fig"}). Unprocessed Msb2p accumulated in the *yps1Δ* mutant under this condition ([Fig. 3 B](#fig3){ref-type="fig"}). To determine how Yps1p regulates Msb2p processing in a nutrient-dependent manner, we turned to the expression of the *YPS1* gene, which is highly regulated ([@bib21]). Expression of *YPS1* was induced under nutrient-limiting conditions that promote filamentous growth ([Fig. 3 C](#fig3){ref-type="fig"}). Overexpression of *YPS1* or *MKC7/YPS2* from a high-copy plasmid or inducible promoter stimulated Msb2p-dependent MAPK activity ([Fig. 3 D](#fig3){ref-type="fig"}) and polarized growth ([Fig. 3 E](#fig3){ref-type="fig"} and not depicted). Cells lacking Yps1p were partially defective for MAPK activity, and this effect was exacerbated in cells lacking Mkc7p and Yps3p ([Fig. 3 D](#fig3){ref-type="fig"}). Therefore, Msb2p processing is regulated by starvation-dependent induction of its cognate protease. Cleavage by Yps1p may trigger Msb2p activation or be a prerequisite for activation.

Activated Msb2p functions through Sho1p
---------------------------------------

Msb2p interacts with the tetraspan protein Sho1p ([@bib11]). The C-terminal domain of Msb2p was sufficient to recapitulate the Msb2p--Sho1p interaction ([Fig. 4 A](#fig4){ref-type="fig"}). To better understand the role of Sho1p in Msb2p-dependent signaling, alleles of *SHO1* were isolated that hyperactivate the filamentous growth pathway. A dominant gain-of-function allele was identified by random mutagenesis that encodes a P120L change in the short DGPKK linker of the second extracellular loop of the protein ([Fig. 4 B](#fig4){ref-type="fig"}). The mutation at P120L did not affect Sho1p protein levels ([Fig. 4 B](#fig4){ref-type="fig"}) but stimulated the filamentous growth pathway based on hyperpolarized growth of haploid and diploid cells ([Fig. 4 C](#fig4){ref-type="fig"}), agar invasion phenotypes (Fig. S2 A, available at <http://www.jcb.org/cgi/content/full/jcb.200704079/DC1>), and induction of filamentous growth pathway reporters (Fig. S2 B). Sho1p^P120L^ functioned normally in the HOG pathway (Fig. S2, C--F). Other alleles of *SHO1* that differentially influence its function between pathways map to the cytoplasmic SH3 domain and affect the Sho1p--Pbs2p interaction ([@bib28]; [@bib49]; [@bib47]). The P120L mutation maps to the tetraspan domain that is thought to be dispensable for Sho1p function in the HOG pathway ([@bib32]) and may identify a region of the protein that specifically regulates Sho1p function in the filamentous growth pathway.

![**Msb2p induces MAPK activation through Sho1p.** (A) Co-IPT analysis of Sho1p-HA with N- and C-terminally tagged Msb2p-GFP. IPT, immunoprecipitation; WCE, whole cell extract. Proteins were tagged and precipitated with the indicated epitopes. The asterisks indicate the bands that correspond to GFP. Molecular mass standards (kD) are indicated on the left of the gel blots. (B) Alleles of *SHO1* (P120L and S220F) that hyperactivate the filamentous growth pathway. (bottom) Western blot of Sho1p-HA protein levels. (C) Sho1p^P120L^ induces hyperpolarized growth in haploid (in SC-Glu) and diploid cells (in SLAHD). (D) *FUS1-lacZ* expression in strains containing alleles of *SHO1* and *MSB2*. Error bars represent the standard deviation of the values derived from at least two separate experiments. (E) Cell morphology induced by Sho1p^P120L^ and Msb2p-HA^Δ100-818^ in the indicated strains grown in SCD medium. Bars: (C) 5 μm; (E) 20 μm.](jcb1811073f04){#fig4}

Gain-of-function alleles of *MSB2* and *SHO1* were used to explore the functional relationships between the cell-surface proteins. Activated versions of Msb2p were dependent on Sho1p for MAPK signaling ([Fig. 4 D](#fig4){ref-type="fig"}) and hyperpolarized growth ([Fig. 4 E](#fig4){ref-type="fig"}). In contrast, Sho1p^P120L^ partially induced MAPK signaling ([Fig. 4 D](#fig4){ref-type="fig"}) and hyperpolarized growth ([Fig. 4 E](#fig4){ref-type="fig"}) in the absence of Msb2p. Sho1p^P120L^ also restored MAPK activity to the Msb2p^ΔCD^ strain and the *yps1Δ mkc2Δ yps3Δ* mutant (not depicted). This property reflects a change in the activation state of Sho1p, as another gain-of-function allele that was present at higher levels (S220F; [Fig. 4 B](#fig4){ref-type="fig"}), or overexpression of *SHO1*, failed to bypass *msb2*Δ ([Fig. 4 D](#fig4){ref-type="fig"}, shown for S220F). These results indicate that MAPK signaling is initiated by Msb2p and propagated through Sho1p. This conclusion may oversimplify the relationship between the proteins as they show some degree of interdependence ([Fig. 4 D](#fig4){ref-type="fig"}, *SHO1*^P120L^ in WT compared with *msb2*Δ) but is nevertheless consistent with the idea that cleavage of Msb2p is an early or initial event in MAPK activation.

Sho1p contributes to guanine nucleotide exchange factor (GEF) polarization by multiple mechanisms
-------------------------------------------------------------------------------------------------

Msb2p interacts with the GTPase Cdc42p ([@bib11]) and has genetic interactions with the GEF Cdc24p ([@bib3]). *CDC24* showed genetic interactions with *SHO1* and other filamentous growth pathway components (Fig. S3 A, available at <http://www.jcb.org/cgi/content/full/jcb.200704079/DC1>). The Cdc24p protein also associated with Sho1p ([Fig. 5 A](#fig5){ref-type="fig"}); an interaction with Msb2p was not detected (not depicted). Given the complex associations between receptors and GEFs in other contexts ([@bib29]), it is possible that the Sho1p--Cdc24p interaction is mediated by other proteins. We also tested for an interaction between Sho1p and the positional marker Bud8p ([@bib16]), which is required for unipolar budding during filamentous growth ([@bib46]; [@bib9]) and for GEF recruitment during vegetative growth by the bud-site selection GTPase Rsr1p ([@bib42]). Sho1p and Bud8p were found to associate ([Fig. 5 B](#fig5){ref-type="fig"}). These results are consistent with the idea that Sho1p contributes to Bud8p-dependent recruitment of Cdc24p by a mechanism that requires MAPK activation. Sho1p and Cdc24p might interact by affiliation with bud-site selection proteins; however, the Sho1p--Cdc24p interaction was independent of Rsr1p ([Fig. 5 A](#fig5){ref-type="fig"}) and Bud8p ([Fig. 5 C](#fig5){ref-type="fig"}). Hyperactive alleles of *SHO1*, or its overexpression, induced hyperpolarized growth in a manner that was partially independent of bud-site selection cues and the MAPK pathway ([Fig. 5 D](#fig5){ref-type="fig"}). These results indicate that Sho1p may also have a function in stabilization of Cdc24p at polarized sites.

![**Sho1 interacts with Cdc24p and Bud8p and contributes to Cdc24p polarization by multiple mechanisms.** (A) Sho1p and Cdc24p interact by co-IPT analysis. Proteins were tagged and precipitated with the indicated epitopes. (B) Sho1p and Bud8p interact by co-IPT analysis. (C) The interaction between Sho1p and Cdc24p is independent of Bud8p. Molecular mass standards (kD) are indicated on the left of the gel blots. (D) The length of cells overexpressing *SHO1* in WT, *ste12Δ*, and *rsr1Δ* strains compared with a WT control. More than 50 cells were examined for each strain. Error bars represent the standard deviation of the values derived from at least two separate experiments.](jcb1811073f05){#fig5}

Summary
-------

We have identified a novel MAPK activation mechanism in yeast by processing and release of the inhibitory domain of Msb2p. Cleavage-dependent activation has been found for Notch ([@bib41]) and PAR receptors ([@bib1]) and may extend to other members of the signaling mucin family. We have also identified a glycosylphosphatidylinositol (GPI)-anchored aspartyl protease that regulates Msb2p function. In mammalian cells, secreted aspartyl proteases are coregulated with signaling mucins ([@bib24]), which suggests the possibility that aspartyl proteases may be general regulators of signaling mucin receptors.

Materials and methods
=====================

Strains, plasmids, and microbiological techniques
-------------------------------------------------

Yeast strains are listed in Table S1 (available at <http://www.jcb.org/cgi/content/full/jcb.200704079/DC1>) and plasmids in Table S2. β-galactosidase assays were performed as described and represent at least two independent trials ([@bib10]). *FUS1-HIS3* expression was used to confirm *FUS1-lacZ* reporter data and was measured by spotting equal amounts of cells onto synthetic medium lacking histidine and containing 4-amino-1,2,4-triazole. Unless otherwise indicated, the locations of the epitope tags are at 500 residues for Msb2p and at 367 residues for Sho1p. HA-Msb2p-GFP contains a GFP epitope at position 1,306 residues. All fusion proteins were functional with respect to filamentation phenotypes and MAPK reporter activity. Other functional C-terminal Msb2p fusions show similar processing intermediates as Msb2p-GFP.

Yeast and bacterial strains were manipulated by standard methods ([@bib39]; [@bib37]). The budding pattern was based on established methodology ([@bib7]) and by visual inspection as described previously ([@bib9]) using the single cell invasive growth assay ([@bib8]). The plate-washing assay ([@bib35]) and pseudohyphal growth assay ([@bib13]) were performed as described previously.

The plasmid containing the *MSB2* gene (pMSB2; PC1287) was identified in a genetic screen for high-copy suppressors of the signaling defect of an *msb2*Δ mutant (PC948) using a galactose-inducible plasmid library ([@bib33]). The *MSB2* gene was expressed in the opposite orientation with respect to the *GAL* promoter and was *GAL* independent. Plasmid pHA-MSB2 (PC1456) was created by GAP repair using homologous recombination of plasmid p*MSB2* in strain PC999. p*MSB2-GFP* was constructed by PCR amplification and insertion of the GFP cassette into p*MSB2* at position 400 residues and was constructed by A. Mirando (University of Rochester Medical Center, Rochester, NY). Plasmids containing filamentous growth pathway targets fused to *lacZ* and plasmid V84 were provided by C. Boone (University of Toronto, Ontario, Canada; [@bib34]). Plasmid pIL30-*URA3* containing FgTy-*lacZ* was provided by B. Errede (University of North Carolina, Chapel Hill, NC; [@bib22]), and p*FRE-lacZ* was provided by H. Madhani (University of California, San Francisco, San Francisco, CA; [@bib26]). Other plasmids containing versions of Sho1p were provided by H. Saito (University of Tokyo, Tokyo, Japan) and A. Davidson (University of Toronto). The HA fusions at the *MSB2* locus were made at 500 residues or other regions of the Msb2p protein as indicated ([@bib40]). Gene disruptions and *GAL1* promoter fusions were made by PCR-based methods ([@bib2]; [@bib25]), including the use of antibiotic resistant markers ([@bib14]). Integrations were confirmed by PCR analysis and phenotype.

Protein analysis
----------------

Secreted proteins were analyzed from conditioned media that was passed through a 2-μm filter to remove cells. Western blots were performed as described previously ([@bib11]). Monoclonal mouse anti-HA antibodies (12CA5.16.4), monoclonal goat anti-GFP antibodies (Rockland Scientific International), and monoclonal antibodies to Dpm1p were used.

Coimmunoprecipitation (co-IPT) analysis
---------------------------------------

To examine the interaction between Sho1p and Cdc24p, co-IPT analysis was performed on extracts derived from PC1652. To measure the interaction in a strain lacking Rsr1p, co-IPT analysis was performed from extracts derived from PC2281. For the Sho1p--Bud8 interaction, PC2249 was transformed with pBUD8-GFP (PC1883) and a control plasmid.

Co-IPT analysis was based on previous methodology ([@bib20]). 100 ml of exponentially grown cells were pelleted at room temperature for 5 min at 3,000 *g*. Cells were resuspended in 4 ml of DTT buffer (50 mM Tris-HCl, pH 7.5, and 10 mM DTT) and incubated at room temperature for 15 min. The cells were pelleted at room temperature for 5 min at 15,800 *g*, and pellets were resuspended in 3.75 ml of spheroplast buffer (1.2 M sorbitol, 50 mM potassium phosphate, pH 7.4, 1 mM MgCl, and 250 μg/ml of zymolyase) and incubated in 30°C on an end-to-end rotator for 1 h. Spheroplasts were centrifuged for 2 min at 2,300 *g*. Cell pellets were washed in 1 ml of 1.2 M sorbitol and centrifuged for 4 min at low speed as before. Spheroplasts were lysed in 1 ml of ice-cold IPT buffer (50 mM Tris-HCl, pH 8, 1 mM EDTA, 50 mM NaCl, and 1.5% Igepal CA-630) supplemented with 1× protease inhibitor cocktail, EDTA free, and 1 mM PMSF before use. Lysates were centrifuged at 4°C for 20 min at 15,800 *g*. Supernatants were precleared by incubating with 75 μl of immobilized Protein G plus (Thermo Fisher Scientific) on an end-to-end rotator for 30 min. Beads were pelleted at 4°C for 10 min at 15,800 *g*. The protein concentration of precleared supernatants was determined by the Bradford Coomassie blue assay. 5--7 mg of proteins were immunoprecipitated with a polyclonal antibody in 1:75 dilution for 1 h, and complexes were pulled down by adding 75 μl of protein G and incubating for another 1 h. IPT complexes were pelleted at 15,800 *g* for 1 min. Beads were washed in IPT buffer three times for 1 min each time. 50 μl of Thorner buffer (8 M urea, 5% SDS, 40 mM Tris-HCl, pH 6.8, 0.1 M EDTA, 0.4 mg/ml Bromophenol blue, and 1% β-mercaptoethanol) was added to beads, and IPT complexes were released from beads by boiling for 10 min. Beads were removed by centrifuging for 1 min at 15,800 *g*, after which the pellet was discarded. Supernatants (protein complexes) were either immediately processed by SDS-PAGE or frozen at −80°C.

Microscopy
----------

Differential interference contrast and fluorescence microscopy of the GFP protein using FITC filter sets were performed using an fluorescent microscope (Axioplan 2; Carl Zeiss, Inc.) with a Plan-Apochromat 100×/1.4 (oil) objective (NA 0.17; Carl Zeiss, Inc.). For most experiments, cells were visualized by resuspending in water at 25°C. Digital images were obtained with a camera (Axiocam MRm; Carl Zeiss, Inc.). Axiovision 4.4 software (Carl Zeiss, Inc.) was used for image acquisition and analysis. Images were further analyzed in Photoshop (Adobe), where adjustments of brightness and contrast were made.

SHO1 mutagenesis
----------------

Mutagenesis of the *SHO1* gene was performed by plasmid mutagenesis based on a protocol for direct transformation into yeast ([@bib36]). Efficiency was 5% as determined by the frequency of *sho1* null mutations. An allele of *SHO1* was used (S171C and NF300GSA; [@bib28]) that fully complemented the *sho1Δ* mutant. Hyperactive alleles were selected on media lacking histidine and containing 4-amino-1,2,4-triazole using the *FUS1-HIS3* reporter (PC1531) integrated into *ste4Δ* Σ1278b strains ([@bib11]). 283,680 URA3+ colonies were screened and ∼100 ATA resistant isolates were identified, of which six were plasmid dependent; five of the six resulted in the P120L change and were identified in separate pools. Plasmid-dependent mutations were analyzed by sequence analysis at the Roswell Park sequencing facility.

Western blots and protein analysis
----------------------------------

Proteins were separated by SDS-PAGE on 10% precast gels (Bio-Rad Laboratories) and transferred to nitrocellulose membranes (protran BA85, VWR International, LLC). Membranes were incubated in 10 ml of blocking buffer (5% nonfat dry milk, 10 mM Tris-HCl, pH 8, 150 mM NaCl, and 0.05% Tween 20) either for 1 h at 25°C or 16 h at 4°C. Preblocked membranes were incubated in blocking buffer containing primary antibodies for 1 h at 25°C. Blots were washed three times for 5 min each in TBST (10 mM Tris-HCl, pH 8, 150 mM NaCl, and 0.05% Tween 20). Blots were incubated in HRP-conjugated secondary antibodies for 1 h at room temperature. ECL Plus Western blotting reagent (GE Healthcare) was used to detect proteins. Predicted N- and O-glycosylation sites were determined by O-GLYCBASE version 2.0 (Center for Biological Sequence Analysis, Technical University of Denmark; [@bib15]). The secondary structure of Msb2p domains was determined by PROF and NORS algorithms ([@bib38]).

Online supplemental material
----------------------------

Fig. S1 shows the secretion defect of Msb2p in *yps* and cell wall mutant combinations. Fig. S2 shows analysis of the *SHO1*^P120L^ allele. Fig. S3 shows genetic data between filamentous growth pathway components and Cdc24p. Table S1 lists yeast strains. Table S2 lists plasmids used in this study. Table S3 shows analysis of secretion of the Msb2p-HA protein in protease mutants. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.200704079/DC1>.
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